A typical psychiatrist spends 20 to 30 minutes with patients during medication visits. Those rare birds who still do therapy can devote 40 to 50 minutes. Either way, that’s not a lot of time in comparison to the rest of our patients’ lives, nor in comparison to the size of their problems.

We couldn’t quite fit all of our reviews into this issue. Listed below are some more excellent books, all of which qualified for “honorable mention.”

After innumerable articles and books on the importance of genetic variants of P450 enzymes, it appears that the clinical pay-off just might be at hand.

Genetic counseling in psychiatry is a tricky proposition, because we are just starting to understand the complexity that underlies the genetic basis of psychiatric disease.

As science continues to explore the genetic components of mental illness, concerns about eugenics cannot be far behind. Long before the days of prenatal diagnosis, and difficult decisions about whether or not to terminate a pregnancy, there was a debate in the pages of the American Journal of Psychiatry in 1942 about actually killing so-called “feebleminded” people.

Are antidepressants hazardous to a neonate’s health? The FDA implied as much this past summer, when they issued a new precaution and required all antidepressant makers to include something like this text (for Effexor) in their package inserts …

What is postpartum depression (PPD), and why does it occur? PPD is generally defined as major depressive symptoms occurring within three months of childbirth. Don’t confuse PPD with the very common postpartum blues, a phenomenon that occurs in over half of women who give birth, peaks about four days after delivery, and fully remits by 10 days postpartum (N Engl J Med 2002; 347:194-199).

“You can use vitamins to help a woman through those things,” said Tom Cruise, denigrating Brooke Shields’s use of an SSRI to treat her postpartum depression, which she detailed in her recent book Down Came The Rain: My Journey Through Postpartum Depression.

Suddenly, putting patients to sleep is all the rage in psychiatry. Over the last year, two new hypnotics have been approved by the FDA – Lunesta (eszopiclone) in December 2004 and Rozerem (ramelteon) in July 2005. Indiplon (the generic name) is on the launching pad for approval in early 2006.

Tapering patients off benzos (BZs) is certainly more art than science, but TCR has unearthed a surprising number of studies that help bring more science into the process. These studies are, by modern standards, ancient, because research follows the money, and there’s no longer much money to be made in benzodiazepines. So file these studies under “oldies but goodies”!